Kopran Limited (KOPRAN) Fair Value & Analysis
Healthcare · IN · Market cap ₹9.5B
Risks
Fair value as of: Aug 25, 2026
From 14 valuation models · updated today
Share price −0.8% over the past month.
Below-average quality, and trading another 118% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (₹115.83). The favourable scenario is already priced in.
- Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 25, 2026.
How to read this chart
60‑month range ₹92.90 – ₹338.12 · fair‑value band ₹76.27 – ₹115.83 · the ₹193.88 price screens above the ₹89.10 fair value. Dashed = 300-day average. As of Aug 25, 2026.
Analysis
Kopran Limited (KOPRAN) currently trades at ₹193.88, while our model-based Fair Value estimate is ₹89.10, implying the stock looks roughly 54.0% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Kopran Limited generated revenue of ₹6.8B at a net margin of 3.8%. Revenue grew 35.8% year over year. It earns a return on equity of 4.9%. Net debt stands at ₹1.5B. Fundamentals as of Aug 25, 2026
Our scenario range runs from ₹76.27 (bear case) to ₹115.83 (bull case); at ₹193.88, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 81% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -11% fair-value upside, at -54%, KOPRAN screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Multiples (₹117.24) versus Earnings-Based (₹47.11). Highest evidence: Residual Income (76).
Notify me when KOPRAN reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 25, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 65
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally.
Full company description
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, penicillin, quinolone, anti-protozoal, sulphonamides, respiratory, tetracycline, cardiovascular, anti-diabetic, urology, pain management and anti-inflammatory, gastrointestinal, erectile dysfunction, anthemintic, anti-allergic, central nervous system, anti-malarial, anti-thyroid, and carbapenems. In addition, the company offers drugs for anti-hypertensive, neuromodulator, anti-acne, anti-infective, antibiotic, anti-thrombotic, anti-diabetic, anti-asthamatic, antihyperlipidemic, anti-convulsants, anti-anxiety, pulmonary arterial hypertension, chronic heart failure, neuropathic pain, and erosive esophagitis. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Kopran Limited reported revenue of ₹6.8B in FY2026 versus ₹4.7B in FY2022, a compound +9.5%/yr. Reported net income was ₹257M in FY2026, compounding −19.4%/yr from FY2022.
of which total revenue +9.2 pp · buybacks/dilution −1.4 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
KOPRAN screens 54% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 75 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,220 | $389.47 | -68% |
| Johnson & Johnson, JNJ | $260.86 | $169.04 | -35% |
| AbbVie Inc ABBV | $248.76 | $67.72 | -73% |
| Roche Holding RO | CHF 370.40 | CHF 306.54 | -17% |
| Merck & Co MRK | €115.42 | €118.21 | +2% |
| Novartis AG NOVN | CHF 127.12 | CHF 113.18 | -11% |
| Novo Nordisk A/S NOVOB | kr 296.35 | kr 409.46 | +38% |
| Amgen Inc AMGN | $442.36 | $252.02 | -43% |
| Gilead Sciences, Inc GILD | $135.87 | $146.50 | +8% |
| Pfizer Inc PFE | $26.31 | $24.87 | -5% |
Compare Kopran Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Kopran Limited (KOPRAN) overvalued or undervalued?
What is the fair value of KOPRAN?
What is the quality score of KOPRAN?
What is the revenue of Kopran Limited (KOPRAN)?
What is the net profit margin of KOPRAN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Kopran Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.